U.S. gives full approval to 1st COVID-19 drug for young children
Global News
The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc's GILD.O drug remdesivir.
More Related News